A new initiative by Google may provide new tools and medical laboratory tests that can be used in the management of geriatric patients.
Google’s founders believe that analysis of the genomes of people who live to be 100 years old and are relatively healthy will allow them to solve the puzzle of human aging. They have funded a new company, Calico — short for California Life Company, to pursue this goal. The research should develop a better understanding of the dynamics of human aging and the diseases associated with it.
Calico is backed by Google Ventures. The idea was developed by its Managing Partner, Bill Maris. Google co-founders Larry Page and Sergey Brin are also involved. They are throwing hundreds of millions of dollars into launching another world-changing “moonshot.”
Calico to Marry High-Tech’s Big Data Techniques with Medical Research
Maris’ idea was rooted in his understanding of how Big Data analysis could be used to study the genomes of healthy older people who make it to 90 or 100 years old without encountering any significant health issues. The goal is to discover how, in aggregate, they differ from other people, noted an article published on slashgear.com.
Big Data Techniques Will Come into Play
Interplay between high-tech and medical research communities is becoming more common. In fact, a number of companies are using big data to analyze health issues in large population studies. For example, researchers involved in the Cohorts for Heart and Aging Research in Genomic Epidemiology, or CHARGE are using big data techniques in a large-scale genetic sequencing project aimed at linking particular diseases and specific genetic variants.
Calico’s Goal is Personal for Google Founders
“Illness and aging affect all our families,” declared Page in an announcement of Calico’s launch on Google’s blog. “With some longer-term, moonshot thinking around healthcare and biotehnology, I believe we can improve millions of lives.” Both Page and Brin have been touched by major illness.
Brin, whose mother had Parkinson’s disease, is also at high risk for this disease. Page suffers from a rare nerve disease that affects his voice by restricting movement of his vocal chords.
The Genius Driving Calico’s Anti-aging Goal
Page told Time Magazine in a story about Calico that, like Google, Calico’s approach will be unconventional. He is relying on Levinson’s genius to carry this off. Levinson, also a founding investor in Calico, is the former CEO of Genetech, Inc.. He is currently Chairman of the Board at both Apple, Inc., and Genetech, as well as a member of Google’s board of directors.
Even David Brailer, M.D., weighed in on the goal of defeating aging. He is CEO of Health Evolution Partners, a private equity firm that invests in the healthcare industry. Brailer told the LA Times, “Extending life is about as high as it gets on the human scale. It’s obviously a profoundly an important goal. It’s one of those things that is close to impossible, but you have got have got the right guy to tackle it,” he observed. “This is about Art [Levinson], about his ability to convene the right people to focus on an agenda that is realistic and bring a very pragmatic approach… I am intrigued by it and can’t wait to hear more.”
Assembling Accomplished Scientists
Levinson’s scientific team, noted an article published by nextbigfuture.com, includes a number of the most accomplished scientists in the fields of medicine, drug development, molecular biology and genetics.
Cynthia Kenyon, Ph.D., one of the world’s foremost authorities on molecular biology and the genetics of aging and life extension, will serve as Calico’s as Senior Scientific Advisor. A UCSF American Cancer Society Professor and former President of the Genetics Society of America, her pioneering discovery of a single-gene mutation that could double the lifespan of healthy, C. Elegansroundworms sparked an intensive study of the molecular biology of aging, noted a report published by nextbigfuture.com.
Creating All-Star Scientific Research Teams
At a minimum, Calico represents a developing trend in healthcare research because it is engaging a variety of world-class scientists to participate at the board and executive levels. In that respect, it can be compared to the all-star teams assembled in professional sports. Furthermore, pathologists and clinical laboratory managers can expect competition in this space. In recent weeks, J. Craig Venter, Ph.D., has disclosed his plans to study human aging and has organized a new company, Human Longevity, Inc., to pursue this goal.